Patent: 6,306,874
✉ Email this page to a colleague
Summary for Patent: 6,306,874
Title: | Tyrosine kinase inhibitors |
Abstract: | The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals. |
Inventor(s): | Fraley; Mark E. (North Wales, PA), Arrington; Kenneth L. (Elkins Park, PA), Bilodeau; Mark T. (Lansdale, PA), Hartman; George D. (Lansdale, PA), Hoffman; William F. (Lansdale, PA), Kim; Yuntae (Harleysville, PA), Hungate; Randall W. (Newbury Park, CA) |
Assignee: | Merck & Co., Inc. (Rahway, NJ) |
Application Number: | 09/690,598 |
Patent Claims: | see list of patent claims |
Details for Patent 6,306,874
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2019-10-19 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2019-10-19 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2019-10-19 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |